Status:
NO_LONGER_AVAILABLE
Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients
Lead Sponsor:
APT Pharmaceuticals, Inc.
Conditions:
Lung Transplant
Eligibility:
All Genders
Brief Summary
Currently there are no approved therapies for lung transplant recipients in the United States (US). Treatment with CIS following lung transplantation has previously been demonstrated to result in a cl...
Eligibility Criteria
Inclusion
- Single-or double-lung transplant recipients who have a high risk for developing chronic rejection
- Single or double-lung transplant recipients who have developed chronic rejection
- Single or double-lung transplant recipients who have serious or life-threatening complications of systemic immunosuppressive therapy
Exclusion
- Known hypersensitivity to cyclosporine or propylene glycol (PG)
- Females who are pregnant or are considering becoming pregnant
- Females who are breast feeding a child.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00633373
Last Update
September 17 2012
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at San Francisco
San Francisco, California, United States, 94143
2
University of Florida Health Sciences Center
Gainesville, Florida, United States, 32610
3
Tampa General Hospital
Tampa, Florida, United States, 33606
4
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201